You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 11,273,160

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,273,160

Title:	RET inhibitor for use in treating cancer having a RET alteration
Abstract:	Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
Inventor(s):	Evans Raab; Erica (Cambridge, MA), Wolf; Beni B. (Cambridge, MA)
Assignee:	BLUEPRINT MEDICINES CORPORATION (Cambridge, MA)
Application Number:	17/127,041
Patent Claims:	1. A method of treating a subject with a rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC), comprising orally administering to the subject with a RET-altered NSCLC once daily 100 mg to 400 mg of Compound 1, wherein Compound 1 is: ##STR00003## 2. The method of claim 1, wherein the NSCLC is metastatic NSCLC. 3. The method of claim 1, wherein the NSCLC has a RET mutation or a RET-gene rearrangement. 4. The method of claim 3, wherein the RET-gene rearrangement is a RET fusion. 5. The method of claim 4, wherein the RET fusion is selected from the group consisting of KIF5B-RET, CCDC6-RET, NCOA4-RET, TRIM33-RET, KIAA1217-RET, and MPRIP-RET. 6. The method of claim 4, wherein the RET fusion is KIF5B-RET. 7. The method of claim 4, wherein the RET fusion is CCDC6-RET. 8. The method of claim 1, wherein the subject was previously treated with platinum. 9. The method of claim 8, wherein the subject was previously treated with cisplatin or carboplatin. 10. The method of claim 1, wherein the subject is orally administered 100 mg of Compound 1 once daily. 11. The method of claim 1, wherein the subject is orally administered 300 mg of Compound 1 once daily. 12. The method of claim 1, wherein the subject is orally administered 400 mg of Compound 1 once daily. 13. A method of treating a subject with a rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC), comprising orally administering once daily to the subject with the RET-altered NSCLC one or more solid dosage forms each comprising a pharmaceutically acceptable excipient and 100 mg of Compound 1, wherein Compound 1 is: ##STR00004## 14. A method of treating a subject with a metastatic rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC), comprising orally administering to the subject with a RET-altered NSCLC once daily 400 mg of Compound 1, wherein Compound 1 is: ##STR00005##

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.